BACKGROUND: The recently growing interest in targeted alpha-therapy (TAT) calls for improvement of the labelling chemistry of the corresponding radionuclides. 213BiIII is a short-lived alpha emitter which emits only one alpha particle in its decay chain. Hence, it might be safer in application than other respective nuclides, such as 223Ra or 225Ac, because no alpha-emitting daughters are released upon recoil. We investigated cyclen derivatives with phosphorus-containing pendant arms regarding their suitability for 213Bi labelling. RESULTS: The concentration dependency of 213Bi labelling at 25 °C and 95 °C was determined for DOTP, DOTPH, DOTPEt, and DOTPI, as well as for DOTA and CHX-A"-DTPA for comparison. The labelling efficiency of the phosphorus-containing ligands was at least comparable to CHX-A"-DTPA and exceeded that of DOTA. DOTP was most efficient, requiring chelator concentrations for labelling which were approx. two orders of magnitude lower than those required for CHX-A"-DTPA, both at 25 °C and 95 °C. The 213Bi complexes of phosphorus ligands furthermore showed a higher stability against demetallation (> 96% of intact complex after 120-min incubation in plasma were found for DOTP, DOTPH, and DOTPEt, compared to 85% for DOTA and 76% for CHX-A"-DTPA). CONCLUSION: Cyclen derivatives bearing four N-methylenephosphonic or -phosphinic acid substituents, e.g., DOTP, are capable of complexing the alpha-emitting radionuclide 213BiIII with higher efficiency and in-vitro stability than the current gold standards DOTA and CHX-A"-DTPA.

Department of Inorganic Chemistry Charles University Hlavova 2030 12843 Prague 2 Czech Republic

Department of Nuclear Medicine and Department of Obstetrics and Gynecology Technische Universität München Munich Germany

European Commission Joint Research Centre Directorate for Nuclear Safety and Security Karlsruhe Germany

Lehrstuhl für Pharmazeutische Radiochemie Technische Universität München Walther Meißner Strasse 3 85748 Garching Germany

Present address Isotope Technologies Garching GmbH Garching Germany

See more in PubMed

Seidl C. Radioimmunotherapy with α-particle-emitting radionuclides. Immunotherapy. 2014;6:431–458. doi: 10.2217/imt.14.16. PubMed DOI

Pommé S, Marouli M, Suliman G, Dikmen H, Van Ammel R, Jobbágy V, et al. Measurement of the 225Ac half-life. Appl Radiat Isot. 2012;70:2608–2614. doi: 10.1016/j.apradiso.2012.07.014. PubMed DOI

McDevitt MR, Ma DS, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537–1540. doi: 10.1126/science.1064126. PubMed DOI

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New Engl J Med. 2013;369:213–223. doi: 10.1056/NEJMoa1213755. PubMed DOI

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate Cancer. J Nucl Med. 2016;57:1941–1944. doi: 10.2967/jnumed.116.178673. PubMed DOI

Kozempel J, Mokhodoeva O, Vlk M. Progress in targeted alpha-particle therapy. What we learned about recoils release from in vivo generators. Molecules. 2018;23:581. doi: 10.3390/molecules23030581. PubMed DOI PMC

de Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy—how to deal with recoiling daughters? Pharmaceuticals. 2015;8:321–336. doi: 10.3390/ph8020321. PubMed DOI PMC

Morgenstern A, Bruchertseifer F, Apostolidis C. Targeted alpha therapy with 213Bi. Curr Radiopharm. 2011;4:295–305. doi: 10.2174/1874471011104040295. PubMed DOI

Morgenstern A, Bruchertseifer F, Apostolidis C. Bismuth-213 and actinium-225—generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Curr Radiopharm. 2012;5:221–227. doi: 10.2174/1874471011205030221. PubMed DOI

Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–2119. doi: 10.1007/s00259-014-2857-9. PubMed DOI PMC

Allen BJ, Singla AA, Rizvi SM, Graham P, Bruchertseifer F, Apostolidis C, et al. Analysis of patient survival in a phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy. 2011;3:1041–1050. doi: 10.2217/imt.11.97. PubMed DOI

Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37:1335–1344. doi: 10.1007/s00259-010-1385-5. PubMed DOI

Notni J, Wester HJ. Re-thinking the role of radiometal isotopes: towards a future concept for theranostic radiopharmaceuticals. J Label Compd Radiopharm. 2018;61:141–153. doi: 10.1002/jlcr.3582. PubMed DOI

Šimeček J, Hermann P, Havlíčková J, Herdtweck E, Kapp TG, Engelbogen N, et al. A cyclen-based tetraphosphinate chelator for preparation of radiolabeled tetrameric bioconjugates. Chem Eur J. 2013;19:7748–7757. doi: 10.1002/chem.201300338. PubMed DOI

Kotková Z, Pereira GA, Djanashvili K, Kotek J, Rudovský J, Hermann P, et al. Lanthanide(III) complexes of phosphorus acid analogues of H4DOTA as model compounds for the evaluation of the second-sphere hydration. Eur J Inorg Chem. 2009:119–36.

Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005;77:6289–91. PubMed

Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc Perkin Trans 1. 1992:1173–8.

Stasiuk GJ, Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem Commun. 2013;49:2732–2746. doi: 10.1039/c3cc38507h. PubMed DOI

Notni J, Šimeček J, Wester HJ. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications. ChemMedChem. 2014;9:1107–1115. doi: 10.1002/cmdc.201400055. PubMed DOI

Notni J. With Gallium-68 into a new era? Nachr Chem. 2012;60:645–649. doi: 10.1002/nadc.201290233. DOI

Rösch F. Past, present and future of 68Ge/68Ga generators. Appl Rad Isot. 2013;76:24–30. doi: 10.1016/j.apradiso.2012.10.012. PubMed DOI

Hama H, Takamoto S. Polarographic determination of stability constants of divalent metal chelates of 1,4,7-triazacyclononane-N,N',N''-triacetic acid. Nippon Kagaku Kaishi. 1975:1182–5.

Kabachnik MI, Medved TY, Belskii FI, Pisareva SA. Izv Akad Nauk SSSR Ser Khim. 1988;37:1886–1890.

Geraldes CFCG, Sherry AD, Lázár I, Miseta A, Bogner P, Berenyi E, et al. Relaxometry, animal biodistribution, and magnetic resonance imaging studies of some new gadolinium (III) macrocyclic phosphinate and phosphonate monoester complexes. Magn Reson Med. 1993;30:696–703. doi: 10.1002/mrm.1910300607. PubMed DOI

Bazakas K, Lukeš I. Synthesis and complexing properties of polyazamacrocycles with pendant N-methylenephosphinic acid. J Chem Soc Dalton Trans. 1995:1133–7.

Stetter H, Frank W. Complex formation with tetraazacycloalkane-N,N',N",N'"-tetraacetic acids as a function of ring size. Angew Chem Int Ed Engl. 1976;15:686. doi: 10.1002/anie.197606861. DOI

Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem. 1997;5:1925–1934. doi: 10.1016/S0968-0896(97)00130-2. PubMed DOI

Camera L, Kinuya S, Garmestani K, Wu CC, Brechbiel MW, Pai LH, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994;35:882–889. PubMed

Moreau J, Guillon E, Pierrard JC, Rimbault J, Port M, Aplincourt M. Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota)—characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS. Chem Eur J. 2004;10:5218–5232. doi: 10.1002/chem.200400006. PubMed DOI

Ševčík R, Vaněk J, Michalicová R, Lubal P, Hermann P, Santos IC, et al. Formation and decomplexation kinetics of copper(II) complexes with cyclen derivatives having mixed carboxylate and phosphonate pendant arms. Dalton Trans. 2016;45:12723–33. PubMed